IL289039B1 - Ligands for prostate-specific membrane antigen (PSMA) and their uses - Google Patents
Ligands for prostate-specific membrane antigen (PSMA) and their usesInfo
- Publication number
- IL289039B1 IL289039B1 IL289039A IL28903921A IL289039B1 IL 289039 B1 IL289039 B1 IL 289039B1 IL 289039 A IL289039 A IL 289039A IL 28903921 A IL28903921 A IL 28903921A IL 289039 B1 IL289039 B1 IL 289039B1
- Authority
- IL
- Israel
- Prior art keywords
- psma
- ligands
- prostate specific
- specific membrane
- membrane antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184015 | 2019-07-02 | ||
| PCT/EP2020/068386 WO2021001360A1 (en) | 2019-07-02 | 2020-06-30 | Prostate specific membrane antigen (psma) ligands and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL289039A IL289039A (en) | 2022-02-01 |
| IL289039B1 true IL289039B1 (en) | 2026-03-01 |
Family
ID=67145647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289039A IL289039B1 (en) | 2019-07-02 | 2021-12-15 | Ligands for prostate-specific membrane antigen (PSMA) and their uses |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230226227A1 (https=) |
| EP (1) | EP3993837A1 (https=) |
| JP (2) | JP7805170B2 (https=) |
| KR (1) | KR20220044496A (https=) |
| CN (3) | CN114341118A (https=) |
| AR (1) | AR119331A1 (https=) |
| AU (3) | AU2020299974A1 (https=) |
| BR (1) | BR112021026812A2 (https=) |
| CA (1) | CA3144557A1 (https=) |
| CL (1) | CL2021003525A1 (https=) |
| CO (1) | CO2021017708A2 (https=) |
| IL (1) | IL289039B1 (https=) |
| MX (1) | MX2022000136A (https=) |
| PH (1) | PH12021553284A1 (https=) |
| TW (1) | TW202114742A (https=) |
| WO (1) | WO2021001360A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297323A (en) * | 2020-04-29 | 2022-12-01 | Novartis Ag | Methods for radiological labeling of psma-binding ligands and their kits |
| WO2022108992A1 (en) * | 2020-11-17 | 2022-05-27 | The Johns Hopkins University | Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma |
| CN121604981A (zh) | 2023-07-21 | 2026-03-03 | 诺华公司 | 靶向psma的放射性配体治疗方案 |
| WO2025125469A1 (en) | 2023-12-13 | 2025-06-19 | Swiss Rockets Ag | Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018222778A1 (en) * | 2017-05-30 | 2018-12-06 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2415709A1 (en) | 2000-07-11 | 2003-01-10 | Bml, Inc. | Remedies for bone diseases |
| AU2012294639B2 (en) * | 2011-08-05 | 2017-10-26 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
| EP3456700A1 (en) * | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| RS65188B1 (sr) * | 2016-03-22 | 2024-03-29 | Univ Johns Hopkins | Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate |
| US11813340B2 (en) * | 2018-02-06 | 2023-11-14 | The Johns Hopkins University | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
| US20210338846A1 (en) * | 2018-07-30 | 2021-11-04 | The Johns Hopkins University | Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
-
2020
- 2020-06-30 PH PH1/2021/553284A patent/PH12021553284A1/en unknown
- 2020-06-30 MX MX2022000136A patent/MX2022000136A/es unknown
- 2020-06-30 BR BR112021026812A patent/BR112021026812A2/pt unknown
- 2020-06-30 US US17/622,060 patent/US20230226227A1/en active Pending
- 2020-06-30 EP EP20734426.8A patent/EP3993837A1/en active Pending
- 2020-06-30 JP JP2021578240A patent/JP7805170B2/ja active Active
- 2020-06-30 CN CN202080047295.1A patent/CN114341118A/zh active Pending
- 2020-06-30 CN CN202510573926.8A patent/CN120441498A/zh active Pending
- 2020-06-30 CN CN202510573851.3A patent/CN120441497A/zh active Pending
- 2020-06-30 KR KR1020227003148A patent/KR20220044496A/ko active Pending
- 2020-06-30 AU AU2020299974A patent/AU2020299974A1/en not_active Abandoned
- 2020-06-30 WO PCT/EP2020/068386 patent/WO2021001360A1/en not_active Ceased
- 2020-06-30 CA CA3144557A patent/CA3144557A1/en active Pending
- 2020-07-01 AR ARP200101868A patent/AR119331A1/es unknown
- 2020-07-02 TW TW109122386A patent/TW202114742A/zh unknown
-
2021
- 2021-12-15 IL IL289039A patent/IL289039B1/en unknown
- 2021-12-23 CO CONC2021/0017708A patent/CO2021017708A2/es unknown
- 2021-12-28 CL CL2021003525A patent/CL2021003525A1/es unknown
-
2024
- 2024-02-09 AU AU2024200850A patent/AU2024200850B2/en active Active
-
2025
- 2025-07-17 JP JP2025120662A patent/JP2025165975A/ja active Pending
- 2025-11-24 AU AU2025271182A patent/AU2025271182A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018222778A1 (en) * | 2017-05-30 | 2018-12-06 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024200850A1 (en) | 2024-02-29 |
| CO2021017708A2 (es) | 2022-05-20 |
| AU2020299974A1 (en) | 2022-01-27 |
| CN120441498A (zh) | 2025-08-08 |
| JP7805170B2 (ja) | 2026-01-23 |
| BR112021026812A2 (pt) | 2022-02-22 |
| MX2022000136A (es) | 2022-04-27 |
| PH12021553284A1 (en) | 2022-08-01 |
| AU2024200850B2 (en) | 2025-09-04 |
| AU2025271182A1 (en) | 2025-12-18 |
| US20230226227A1 (en) | 2023-07-20 |
| JP2022538478A (ja) | 2022-09-02 |
| CN114341118A (zh) | 2022-04-12 |
| AR119331A1 (es) | 2021-12-09 |
| IL289039A (en) | 2022-02-01 |
| CL2021003525A1 (es) | 2022-10-21 |
| KR20220044496A (ko) | 2022-04-08 |
| EP3993837A1 (en) | 2022-05-11 |
| JP2025165975A (ja) | 2025-11-05 |
| TW202114742A (zh) | 2021-04-16 |
| WO2021001360A1 (en) | 2021-01-07 |
| CN120441497A (zh) | 2025-08-08 |
| CA3144557A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266800A (en) | Prostate-specific membrane antigen-binding protein | |
| IL255424B (en) | Prostate-specific membrane antigen bispecific binding agents and uses thereof | |
| IL289039B1 (en) | Ligands for prostate-specific membrane antigen (PSMA) and their uses | |
| MX2021006235A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| MX2024000742A (es) | Anticuerpos anti-tigit. | |
| IL291299A (en) | Anti-TNFR2 antibodies, preparations containing them and their uses | |
| AU2016258174B2 (en) | Prostate specific membrane antigen binding fibronectin type III domains | |
| PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| ZA201804601B (en) | Psma binding antibody and uses thereof | |
| IL289585A (en) | DLL3-targeted antibodies and uses thereof | |
| IL280321A (en) | Antibodies against CXCR2 and their uses | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL281202A (en) | Anti-TNFRSF9 antibodies and uses thereof | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL283890A (en) | Anti-periostin antibodies and their uses | |
| EP4063387A4 (en) | PSMA ANTIBODIES AND ITS USE | |
| GB201902590D0 (en) | Antibodies and uses thereof | |
| HK40065371A (en) | Prostate specific membrane antigen (psma) ligands and uses thereof |